Total Health

 

Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.

For more info visit our website at Total Health.

 

Videos
03:04

Total Health

ASCO® Direct Michigan Melanoma Updates: mRNA Vaccine Use, Neoadjuvant Nivo + Ipi vs. Adjuvant Nivo in Macroscopic, Resectable Stage 3 Disease

FEATURING Adil Daud
  • 14 views
  • September 14, 2024
33:26

Total Health

GI Cancers Expert Discussion: Pem vs. Gem+Cis for CCA with FGFR2 Fusions, Nivo for Resected EC/GEJC, 1L Chemo vs. Chemo+Pembro for EC, Nivo/Chemo/Nivo+Ipi for HER2- Advanced GC, Chemo+/-Nivo for Advanced GC/GEJC

FEATURING Shikha Jain, May Cho, Cathy Eng, Arturo Loaiza-Bonilla, Aparna Parikh
  • 328 views
  • March 11, 2021
44:02

Total Health

Expert Discussion on mCRC: Pembro vs. Chemo for MSI-H dMMR Disease, Trifluridine/Tipiracil + Bev for Untreated Patients, ctDNA in Postoperative Setting

FEATURING Shikha Jain, May Cho, Cathy Eng, Arturo Loaiza-Bonilla, Aparna Parikh
  • 290 views
  • March 10, 2021
  • 1
12:11

Total Health

Expert Discussion on Advanced Pancreatic Cancers: Olaparib for BRCA-Mutated Metastatic Patients, Preoperative mFOLFIRINOX+/-Hypofractionated RT for BR Disease

FEATURING Shikha Jain, May Cho, Cathy Eng, Arturo Loaiza-Bonilla, Aparna Parikh
  • 64 views
  • March 10, 2021
09:49

Total Health

High-Risk HER2+ BC: How to Manage Neratinib Toxicity Using Dose-Escalation? How to Identify Recurrence & Incorporate Neratinib Into Practice?

FEATURING Francis Arena
  • 34 views
  • February 5, 2021
07:12

Total Health

Does Neratinib Affect IDFS After Adjuvant Trastuzumab? Final Efficacy Results of ExteNET Trial

FEATURING Reshma L. Mahtani, Lee Schwartzberg, Sara Tolaney
  • 62 views
  • January 12, 2021
09:37

Total Health

Adjuvant Pertuzumab & T-DM1 for HER2+ EBC: How Effective Are They?

FEATURING Reshma L. Mahtani, Lee Schwartzberg, Sara Tolaney
  • 15 views
  • January 12, 2021
49:07

Total Health

2020 SABCS Practice Applications in HER2+ MBC: Genomic Risk, T-DXd, HER3-DXd, Tucatinib, Neratinib, and Sequencing Strategies

FEATURING Charles Vogel, Sunil Badve, Hope Rugo, Muaiad Kittaneh, Peggy Johnson
  • 41 views
  • January 11, 2021
32:12

Total Health

2020 SABCS Practice Applications in Breast Cancer: Who Might Benefit From Longer Duration ET? Who Doesn't Need Chemotherapy?

FEATURING Charles Vogel, Sunil Badve, Hope Rugo, Muaiad Kittaneh, Peggy Johnson
  • 688 views
  • January 11, 2021
58:47

Total Health

SABCS 2020 Expert Discussion on BC: Neoadjuvant Chemo, bpCR, CDK4/6 Inhibitors, Dosing Differences, Pros and Cons of Radiation in Older Patients

FEATURING Sramila Aithal, Kristina Mirabeau-Beale, Alvaro Moreno-Aspitia, Anne O'Dea
  • 271 views
  • January 5, 2021
  • 1
62:20

Total Health

SABCS 2020 Expert Discussion on ER+ BC: Neoadjuvant Therapy, KI-67 Prognostic Markers, Endocrinologist Approach, Node-Positive Disease, CDK4/6 Inhibitors

FEATURING Matthew Goetz, Elyse Lower, Terry Mamounas, Kristina Mirabeau-Beale, Salila Kurra, Ann Partridge
  • 29 views
  • January 5, 2021
57:04

Total Health

SABCS 2020 Expert Discussion on TNBC: Molecular Targets, Role of IO, PD-L1, Cost Barriers, Sacituzumab Govitecan

FEATURING Tiffany Traina, Elyse Lower, Terry Mamounas
  • 207 views
  • January 5, 2021
  • 1
91:47

Total Health

SABCS 2020 Expert Discussion on mBC: ER+, HR+, TNBC, HER2+

FEATURING Mark Pegram, Kevin Kalinsky, Sunil Badve, Foluso Olabisi Ademuyiwa, Jennifer Klemp
  • 72 views
  • January 5, 2021
33:36

Total Health

Expert Discussion on 2020 ASCO Updates on IO in mNSCLC: Efficacy Results for Pembro in PD-L1-High Disease, Pembro + Chemo, Nivo + Ipi, Nivo/Ipi + Chemo

FEATURING Millie Das, Gilberto Lopes, Shayma Kazmi, Ravi Salgia
  • 497 views
  • December 10, 2020
28:24

Total Health

Expert Discussion on 2020 ASCO Update on EGFRm NSCLC: How Do ADAURA Results on Adjuvant Osimertinib Affect Clinical Practice?

FEATURING Millie Das, Gilberto Lopes, Shayma Kazmi, Ravi Salgia
  • 334 views
  • December 10, 2020
  • 3
06:46

Total Health

Dose Escalation With Neratinib in Early HER2+ BC: How Should no PCR Patients Be Managed? What Are the Most Important Criteria for the Second Year of Treatment?

FEATURING Yifan Tu
  • 41 views
  • November 13, 2020
08:47

Total Health

Neratinib Dose Escalation in Early Stage HER2+ BC: How to Manage Diarrhea? Can We Incorporate Targeted Therapy for Patients Who Did Not Achieve pCR to Neoadjuvant Chemo?

FEATURING Sramila Aithal
  • 155 views
  • November 13, 2020
  • 1
33:57

Total Health

2020 Update on Molecular Subtyping in BC: Can MammaPrint, BluePrint, and Rapid Genomic Testing Improve Neoadjuvant Decision-Making?

FEATURING Lee Schwartzberg
  • 268 views
  • November 4, 2020
  • 4
06:15

Total Health

2020 ASCO MINDACT Long-Term EBC Follow-Up: Can We De-Escalate in C-High / G-Low Patients? What Is the Function of Ovarian Suppression in Women Under 50?

FEATURING Jennifer Crozier, Ruta Rao
  • 150 views
  • November 4, 2020
06:49

Total Health

2020 ASCO Update on EBC De-Escalation: Can the Use of MammaPrint Spare Patients from Unnecessary Chemotherapy?

FEATURING Martin Dietrich
  • 20 views
  • November 4, 2020
06:09

Total Health

2020 ASCO MINDACT Trial Data on MammaPrint in EBC: Can Genomic Profiling Help Prevent Chemotherapy?

FEATURING Ranju Gupta
  • 13 views
  • November 4, 2020
09:06

Total Health

2020 ASCO Update on EBC: Can MammaPrint Help Identify Patients Who Can Safely Forego Chemo? Why Is it Important to De-Escalate on Younger Pts? Can Ovarian Suppression Determine Which High-Risk Pts Need Chemo?

FEATURING Reshma L. Mahtani
  • 106 views
  • October 27, 2020
28:57

Total Health

Optimizing Therapy for HER2+ EBC in 2020: Do Higher Risk Patients Require Anthracyclines? Do We Always Need a Full Year of Trastuzumab? Can We Use Less Intensive Chemo in Certain Settings?

FEATURING Reshma L. Mahtani, Lee Schwartzberg, Sara Tolaney
  • 205 views
  • October 13, 2020
  • 1
35:32

Total Health

HER2+ MBC in 2020: How Should You Properly Sequence Recently Approved Neratinib, Pertuzumab & T-DM1?

FEATURING Sara Tolaney, Lee Schwartzberg, Reshma L. Mahtani
  • 325 views
  • October 13, 2020
  • 3
14:28

Total Health

2020 Update on Early Stage BC: Is the Benefit Observed in 50+ y/o Women Due to Chemo Effect or Ovarian Suppression?

FEATURING Reshma L. Mahtani
  • 282 views
  • September 28, 2020
08:46

Total Health

2020 Update on De-Escalation in Early Stage BC: Can MammaPrint Help Identify Patients Who May Safely Avoid Chemotherapy?

FEATURING Hope Rugo, Reshma L. Mahtani
  • 139 views
  • September 28, 2020
09:25

Total Health

60 y/o Female with HR+/HER2- Early Stage BC: Will Genomic Information Be Helpful in the Management of This Patient?

FEATURING Hope Rugo, Reshma L. Mahtani
  • 493 views
  • September 28, 2020
  • 1
10:32

Total Health

45 y/o Female With HR+/HER2- What Is Best Early Stage Option for This Patient?

FEATURING Hope Rugo, Reshma L. Mahtani
  • 330 views
  • September 28, 2020
  • 1
07:26

Total Health

Expert Discussion on De-Escalation in Early Stage BC: Which Premenopausal Women With HR+ Disease Need More Therapy Than 5 Years of Tamoxifen? What Is the Ideal Patient to Order MammaPrint?

FEATURING Hope Rugo, Reshma L. Mahtani
  • 810 views
  • September 28, 2020
  • 2
16:07

Total Health

De-escalation MINDACT Trial and the 70-gene MammaPrint Assay in HR+ BC: Can Genomic Profiling Of High-risk Clinical and Pathologic Features Identify Women Who Can Safely Avoid Chemotherapy?

FEATURING William Audeh
  • 631 views
  • August 19, 2020
  • 5
13:31

Total Health

2020 ASCO MINDACT Trial Long Term Follow-up Data in ER+ BC: How Does the 70-gene MammaPrint Assay Support Shared Decision-making for Adjuvant Therapy?

FEATURING William Audeh
  • 219 views
  • August 19, 2020
  • 2